VTP50469 manufacturers
- VTP50469
-
- $176.00 / 1mg
-
2025-04-29
- CAS:2169916-18-9
- Min. Order:
- Purity: 98.31%
- Supply Ability: 10g
- VTP50469
-
- $176.00 / 1mg
-
2024-11-19
- CAS:2169916-18-9
- Min. Order:
- Purity: 98.92%
- Supply Ability: 10g
|
| | VTP50469 Basic information |
| Product Name: | VTP50469 | | Synonyms: | VTP50469;Benzamide, 5-fluoro-N,N-bis(1-methylethyl)-2-[[4-[7-[[trans-4-[(methylsulfonyl)amino]cyclohexyl]methyl]-2,7-diazaspiro[3.5]non-2-yl]-5-pyrimidinyl]oxy]-;Menin-MLL,leukemia,survival,VTP 50469,Epigenetic Reader Domain,antiproliferative,Apoptosis,Inhibitor,protein-protein,VTP-50469,inhibit,VTP50469,differentiation;5-Fluoro-N,N-diisopropyl-2-((4-(7-((trans-4-(methylsulfonamido)cyclohexyl)methyl)-2,7-diazaspiro[3.5]nonan-2-yl)pyrimidin-5-yl)oxy)benzamide;VTP50469, 10 mM in DMSO | | CAS: | 2169916-18-9 | | MF: | C32H47FN6O4S | | MW: | 630.82 | | EINECS: | | | Product Categories: | | | Mol File: | 2169916-18-9.mol |  |
| | VTP50469 Chemical Properties |
| Boiling point | 735.2±70.0 °C(Predicted) | | density | 1.28±0.1 g/cm3(Predicted) | | pka | 10.97±0.40(Predicted) | | form | Solid | | color | White to light yellow |
| | VTP50469 Usage And Synthesis |
| Uses | VTP50469 is a potent, highly selective and orally active Menin-MLL interaction inhibitor with a Ki of 104 pM. VTP50469 has potently anti-leukemia activity[1][2]. | | in vivo | VTP50469 (15-60 mg/kg; oral administration; twice a day; for 28 days; NSG mice) treatment is highly efficacious across all dosage levels and all treatment groups have a significant survival advantage. Mice dosed at 30 and 60 mg/kg VTP50469 extends survival advantage[1]. | Animal Model: | Unconditioned immunodeficient (NSG) mice with MV4;11 cells[1] | | Dosage: | 15 mg/kg, 30 mg/kg, and 60 mg/kg | | Administration: | Oral administration; twice a day; for 28 days | | Result: | Was highly efficacious across all dosage levels and all treatment groups had a significant survival advantage over the control group.
|
| | References | [1] Krivtsov AV, et al. A Menin-MLL Inhibitor Induces Specific Chromatin Changes and Eradicates Disease in Models of MLL-Rearranged Leukemia. Cancer Cell. 2019 Dec 9;36(6):660-673.e11. DOI:10.1016/j.ccell.2019.11.001
[2] Andrei V. Krivtsov, et al. Abstract 4958: VTP50469 is a novel, orally available menin-MLL1 inhibitor effective against MLL-rearranged and NPM1-mutant leukemia. Cancer Resceach. July 2018.Volume 78, Issue 13 Supplement. |
| | VTP50469 Preparation Products And Raw materials |
|